Cohance Lifesciences Reports FY26 Revenue Dip Amid Strategic Shift

Cohance Lifesciences Ltd. reported a 13% year-on-year revenue decline to INR 22.68 billion for FY26. Despite this, the company maintained resilient adjusted EBITDA margins of 21%.

FY26 Results Show Revenue Decline, Margin Strength

The company's total revenue for FY26 dropped 13% year-on-year to INR 22.68 billion. This decline was primarily caused by inventory destocking in two key commercial molecules, which impacted revenue by approximately INR 260 crore, and operational disruptions at the Nacharam site, leading to a loss of INR 610 million.

Despite these pressures, Cohance Lifesciences maintained a resilient adjusted EBITDA margin of 21% on a consolidated basis. Standalone margins reached 24.6%. The company is expanding its Phase 3 pipeline to 10 programs, with two new ventures advancing in the ADC and oligonucleotide segments.

Strategic Shift Towards High-Value Chemistry

Cohance Lifesciences is focusing on becoming a science-led platform, emphasizing high-value areas like Antibody-Drug Conjugates (ADCs) and oligonucleotides. This transition aims to reduce its reliance on a few key molecules and build a more diversified customer base. Management's guidance indicates a gradual recovery, with growth expected to return in the second half of FY27.

Company's Transformation and Leadership

Cohance Lifesciences, formerly Strides Pharma Science, restructured and rebranded to highlight its Contract Development and Manufacturing Organisation (CDMO) business. The acquisition of NJ Bio significantly enhanced its capabilities in advanced biologics. The company appointed Umang Vohra, formerly of Cipla, as its Executive Chairman & Group CEO to lead governance improvements and strategic direction. This shift moves the company from traditional API manufacturing toward science-driven pharmaceutical services for global clients.

Future Focus and Investment Plans

Shareholders can anticipate a renewed focus on high-value, niche pharmaceutical segments like ADCs and oligonucleotides. The company has outlined a path toward recovery, with growth anticipated from H2 FY27. Increased capital expenditure (capex) of INR 3 billion is planned for FY27 to support capacity expansion and infrastructure development for advanced chemistries. Management is actively working to diversify its customer base and reduce reliance on concentrated revenue streams. Strengthening corporate governance and improving information flow are immediate priorities for the new leadership.

Key Risks and Challenges Ahead

Geopolitical tensions in the Middle East are projected to impact Q1 FY27 gross margins by 100-150 basis points due to higher freight and logistics costs. The FY27 outlook is heavily weighted towards the second half, creating potential execution risks in the first half of the fiscal year. The company acknowledges its historical reliance on a few key molecules, which has contributed to recent revenue volatility. Investments in the NJ Bio subsidiary for bioconjugation will require approximately two years to fully translate into restored profitability.

Competitive Landscape

Cohance Lifesciences competes with established players like Laurus Labs Ltd., Divi's Laboratories Ltd., Syngene International Ltd., and Gland Pharma Ltd. While peers such as Divi's excel in API manufacturing and Syngene leads in contract research, Cohance is carving its niche by focusing on complex biologics and advanced CDMO services. Laurus Labs and Gland Pharma also have a strong CDMO presence, making them direct comparators in the evolving specialized pharmaceutical services market.

Key Financial Figures

• Total revenue for FY26: INR 22.68 billion (consolidated)
• Consolidated adjusted EBITDA margin for FY26: 21%
• Standalone adjusted margins for FY26: 24.6%
• Planned capital expenditure for FY27: INR 3 billion
• Capital expenditure in FY26: INR 2.15 billion

Investor Watchlist

Investors should monitor Q1 FY27 performance, which is expected to be a "bottoming out phase" with low revenue and EBITDA. Watch for signs of recovery and growth materializing in the second half of FY27 as guided. Tracking the execution of the planned INR 3 billion capex for FY27 and its deployment towards growth initiatives is key. Also, observe the progress of new commercial launches, customer diversification strategies, and the turnaround and profitability of the NJ Bio subsidiary over the next two years. Assess progress on strengthening corporate governance and information flow under new leadership.